Skip to main content

Advertisement

Table 1 Baseline characteristics of patients

From: Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

  n = 27
Age (yrs) 61.6 ± 10.0
Woman (n,%) 15 (56)
Median disease duration (yrs, p25-p75) 11.2 (4.2- 17.4)
Median number of previous DMARDs (n) 2.5 (2.0- 3.3)
Previously treated with another biological (n, %) 3 (11%)
Rheumatoid factor positive (n,%) 21 (78)
Duration of infliximab therapy (yrs) 3.7 ± 2.3
Interval infliximab infusions (wks) 6.8 ± 2.0
Disease Activity at baseline  
   Remission (n,%) 7 (26)
   Low disease activity (n,%) 6 (22)
   Moderate disease activity (n,%) 11 (41)
   High disease activity (n,%) 3 (11)
DMARD at baseline (n,%) 23 (85)
   Methotrexate (n,%) 17 (63)
   Dose (mg/week) 16.8 ± 5.5
   Azathioprine (n,%) 4 (15%)
Prednisone at baseline (n, %) 5 (19%)
   Dose (mg/day) 5.8 ± 1.8
  1. Variables are expressed as mean ± SD unless stated otherwise.
  2. wks = weeks; mths = months; yrs = years